Intramuscular DNA Vaccination Protocols Mediated by Electric Fields

  • Pieranna Chiarella
  • Emanuela Signori
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1121)

Abstract

Vaccination is historically one of the most important methods for preventing infectious diseases in humans and animals. New insights in the biology of the immune system allow a more rational design of vaccines, and new vaccination strategies are emerging. DNA vaccines have been proposed as a promising approach for introducing foreign antigens into the host for inducing protective immunity against infectious and cancer diseases. Nevertheless, because of their poor immunogenicity, plasmid DNA vaccination strategies need further implementations. Recent data suggest electrotransfer as a useful tool to improve DNA-based vaccination protocols, being able to stimulate both the humoral and cellular immune responses. In preclinical trials, gene electrotransfer is successfully used in prime-boost combination protocols and its tolerability and safety has been demonstrated also in Phase I clinical trials. In this chapter, we report a short comment supporting electrotransfer as an effective strategy to improve DNA-based vaccination protocols and describe the vaccination procedures by plasmid DNA in combination with electrotransfer and hyaluronidase pretreatment in use in our laboratory.

Key words

DNA vaccination Gene electrotransfer Hyaluronidase Plasmid Skeletal muscle 

Notes

Acknowledgments

The authors thank the staff of the Animal Facility at the “Sacro Cuore” Catholic University of Rome for their assistance in animal care.

E.S. thanks the COST Action TD1104 network-EP4Bio2Med Consortium (http://www.electroporation.net).

References

  1. 1.
    Wells DJ (2006) Viral and non-viral methods for gene transfer into skeletal muscle. Curr Opin Drug Discov Dev 9:163–168Google Scholar
  2. 2.
    Zhu J, Martinez J, Huang X et al (2007) Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood 109:619–625PubMedCrossRefGoogle Scholar
  3. 3.
    Molnar-Kimber KL, Sterman DH, Chang M et al (1998) Impact of pre-existing and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 9:2121–2133PubMedCrossRefGoogle Scholar
  4. 4.
    Cohen P (2006) Immunity’s yin and yang. A successful vaccine must first avoid being eliminated by pre-existing immunity before it can promote a protective immune response. IAVI Rep 10:1–5Google Scholar
  5. 5.
    Ellis RW, Gerety RJ (1990) Key issues in the selection of an expression system for vaccine antigens. J Med Virol 31:54–58PubMedCrossRefGoogle Scholar
  6. 6.
    Touihri L, Ahmed SB, Chtourou Y et al (2012) Design of different strategies of multivalent DNA-based vaccination against rabies and canine distemper in mice and dogs. Virol J 9:319PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Li J, Jiang Y, Zhao S et al (2012) Protective efficacy of an H5N1 DNA vaccine against challenge with a lethal H5N1 virus in quail. Avian Dis 56:937–939PubMedCrossRefGoogle Scholar
  8. 8.
    Fredriksen AB, Sandlie I, Bogen B (2012) Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells. Front Oncol 2:154PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Signori E, Iurescia S, Massi E et al (2010) DNA vaccination strategies for anti-tumour effective gene therapy protocols. Cancer Immunol Immunother 59:1583–1591PubMedCrossRefGoogle Scholar
  10. 10.
    Cho HI, Celis E (2012) Design of immunogenic and effective multi-epitope DNA vaccines for melanoma. Cancer Immunol Immunother 61:343–351PubMedCrossRefGoogle Scholar
  11. 11.
    Powell K (2004) DNA vaccines: back in the saddle again? Nat Biotechnol 22:799–801PubMedCrossRefGoogle Scholar
  12. 12.
    Lorenzen N, Lapatra SE (2005) DNA vaccines for aquacultured fish. Rev Sci Tech 24:201–213PubMedGoogle Scholar
  13. 13.
    Kutzler MA, Weiner DB (2008) DNA vaccines: ready for prime time. Nat Rev Genet 9:776–788Google Scholar
  14. 14.
    Chiarella P, Massi E, De Robertis M et al (2007) Adjuvants in vaccines and for immunisation: current trends. Expert Opin Biol Ther 7:1551–1562PubMedCrossRefGoogle Scholar
  15. 15.
    Chiarella P, Massi E, De Robertis M et al (2008) Strategies for effective naked-DNA vaccination against infectious diseases. Recent Pat Antiinfect Drug Discov 3:93–101PubMedCrossRefGoogle Scholar
  16. 16.
    Neumann E, Schaefer-Ridder M, Wang Y et al (1982) Gene transfer into mouse lymphoma cells by EP in high electric fields. EMBO J 1:841–845PubMedGoogle Scholar
  17. 17.
    Okino M, Mohri H (1987) Effects of a high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. Jpn J Cancer Res 78:1319–321PubMedGoogle Scholar
  18. 18.
    Titomirov AV, Sukharev S, Kistanova E (1991) In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA. Biochim Biophys Acta 1088:131–34PubMedCrossRefGoogle Scholar
  19. 19.
    Mir LM (2009) Nucleic acids electrotransfer-based gene therapy (electrogenetherapy): past, current, and future. Mol Biotechnol 43:167–176PubMedCrossRefGoogle Scholar
  20. 20.
    McMahon JM, Signori E, Wells KE et al (2001) Optimisation of electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase—increased expression with reduced muscle damage. Gene Ther 8:1264–1270PubMedCrossRefGoogle Scholar
  21. 21.
    Rosati M, Valentin A, Jalah R et al (2008) Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 26:5223–5229PubMedCrossRefGoogle Scholar
  22. 22.
    Hirao LA, Wu L, Khan AS et al (2008) Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 26:3112–3120PubMedCrossRefGoogle Scholar
  23. 23.
    Otten G, Schaefer M, Doe B et al (2004) Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 22:2489–2493PubMedCrossRefGoogle Scholar
  24. 24.
    Aihara H, Miyazaki J (1998) Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 16:867–870PubMedCrossRefGoogle Scholar
  25. 25.
    Mathiesen I (1999) Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 6:508–514PubMedCrossRefGoogle Scholar
  26. 26.
    Babiuk S, Baca-Estrada ME, Foldvari M et al (2004) Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J Biotechnol 110:1–10PubMedCrossRefGoogle Scholar
  27. 27.
    Widera G, Austin M, Rabussay D et al (2000) Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 164:4635–4640PubMedGoogle Scholar
  28. 28.
    Chiarella P, Massi E, De Robertis M et al (2008) Electroporation of skeletal muscle induces danger signal release and antigen-presenting cell recruitment independently of DNA vaccine administration. Expert Opin Biol Ther 8:1645–1657PubMedCrossRefGoogle Scholar
  29. 29.
    Bergqvist S (1950) Increased reaction to BCG vaccination caused by hyaluronidase. Nord Med 43:955–956PubMedGoogle Scholar
  30. 30.
    Salvioli G, Degli Esposti A, Dina MA (1952) Experimental studies on Salvioli’s diffusing vaccine; study of histobiochemical reactions in vaccination with killed Koch’s bacilli with and without hyaluronidase. Boll Ist Sieroter Milan 31:210–225PubMedGoogle Scholar
  31. 31.
    Tozuka TN, Akira Y, Yaajima T et al (1954) The enhancement of the effect of B.C.G. vaccination with hyaluronidase. J Shinshu Univ 4:39–71Google Scholar
  32. 32.
    Jedrzejas MJ, Stern R (2005) Structures of vertebrate hyaluronidases and their unique enzymatic mechanism of hydrolysis. Proteins 61:227–238PubMedCrossRefGoogle Scholar
  33. 33.
    Stern R, Jedrzejas MJ (2006) Hyaluronidases: their genomics, structures, and mechanisms of action. Chem Rev 106:818–839PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Kreil G (1995) Hyaluronidases: a group of neglected enzymes. Protein Sci 4:1666–1669PubMedCrossRefGoogle Scholar
  35. 35.
    Wiegand R, Brown J (2010) Hyaluronidase for the management of dextrose extravasation. Am J Emerg Med 2:257Google Scholar
  36. 36.
    Rowlett J (2012) Extravasation of contrast media managed with recombinant human hyaluronidase. Am J Emerg Med 9:2102Google Scholar
  37. 37.
    Dubensky TW, Campbell BA, Villareal LP (1984) Direct transfection of viral and plasmid DNA into the liver or spleen of mice. Proc Natl Acad Sci U S A 81:7529–7533PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Favre D, Cherel Y, Provost N et al (2000) Hyaluronidase enhances recombinant adeno-associated virus (rAAV)-mediated gene transfer in the rat skeletal muscle. Gene Ther 7:1417–1420PubMedCrossRefGoogle Scholar
  39. 39.
    Chiarella P, Fazio VM, Signori E (2010) Application of electroporation in DNA vaccination protocols. Curr Gene Ther 10:281–6PubMedCrossRefGoogle Scholar
  40. 40.
    Chiarella P, De Santis S, Fazio VM, Signori E (2013) Hyaluronidase contributes to the early inflammatory events induced by electrotransfer on the mouse skeletal muscle. Hum Gene Ther 24:406–16PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Pieranna Chiarella
    • 1
    • 2
  • Emanuela Signori
    • 1
    • 2
  1. 1.Laboratory of Molecular Pathology and Experimental OncologyCNR-IFTRomeItaly
  2. 2.Laboratory of Molecular Medicine and BiotechnologyCIR, University Campus Bio-Medico of RomeRomeItaly

Personalised recommendations